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ABSTRACT 
Failure to translate successful neuroprotective preclinical data to a clinical setting in Alzheimer’s 
disease (AD) indicates that amyloidopathy and tauopathy alone provide an incomplete view of 
disease. We have tested here the relevance of additional homeostatic deviations that result from loss 
of activity of transcription factor NRF2, a crucial regulator of multiple stress responses whose 
activity declines with ageing. A transcriptomic analysis demonstrated that NRF2-KO mouse brains 
reproduce 7 and 10 of the most dysregulated pathways of human ageing and AD brains, respectively. 
Then, we generated a mouse that combines amyloidopathy and tauopathy with either wild type (AT-
NRF2-WT) or NRF2-deficiency (AT-NRF2-KO). AT-NRF2-KO brains presented increased markers 
of oxidative stress and neuroinflammation as well as higher levels of insoluble phosphorylated-TAU 
and Aβ*56 compared to AT-NRF2-WT mice. Young adult AT-NRF2-KO mice exhibited deficits in 
spatial learning and memory and reduced long term potentiation in the perforant pathway. This study 
demonstrates the relevance of normal homeostatic responses that decline with ageing, such as NRF2 
activity, in the protection against proteotoxic, inflammatory and oxidative stress and provide a new 
strategy to fight AD. 
 
Graphical abstract 
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INTRODUCTION 
 In spite of the efforts made over the last decades, the etiology of Alzheimer’s disease (AD) 
remains largely unknown. This is in part caused by incomplete reproduction of the human pathology 
in animal models merely exhibiting the proteinopathy associated to deposition of amyloid-beta (Aβ) 
and hyperphosphorylation of TAU. Current AD-models do not reflect molecular mechanisms that 
correlate with the general decline of homeostatic capacity during ageing and may contribute 
significantly to the disease process. These mechanisms include oxidative, inflammatory and 
metabolic stress, which may precede the proteinopathy in prodromal and early phases of sporadic 
AD [1]. 
In this study, we have addressed this problem in the context of deficiency in the Nuclear 
factor (erythroid-derived 2)-like 2 (NRF2), the master regulator of homeostatic responses [2; 3; 4; 5; 
6]. The NRF2 transcriptional signature provides an armamentarium to adapt reactive oxygen species 
signaling, inflammation and metabolism to normal physiological needs [7; 8]. Its transcriptional 
aciviy declines with ageing [9; 10]. Also, in Hutchinson-Gilford progeria syndrome, characterized by 
premature ageing, NRF2 is mislocated in the nuclear periphery, resulting in impaired NRF2 activity 
and consequently increased chronic oxidative stress while NRF2-activators restore viability in an 
animal model of this syndrome [11]. Moreover, male mice pharmacologically treated with a NRF2-
activator exhibit longer lifespan [12]. 
Ageing is the main risk factor for AD and some scattered studies have noted the correlation 
between deficits in NRF2 and AD. In humans, one haplotype allele in the NFE2L2 gene promoter, 
coding NRF2, was associated with an earlier onset of AD, implying that common variants of the 
NFE2L2 gene might affect AD progression [13]. In animal models, the relevance of NRF2 has been 
analyzed in transgenic mice with amyloidopathy [14; 15] or tauopathy [16; 17], but not combined, 
and the main focus was on the role of NRF2 in proteostasis.  
Here, we have performed a transcriptomics study comparing pathways altered in elderly and 
AD brains with those of NRF2-knockout mouse brains. From this reverse translational approach, we 
have further combined expression of the human APP
V717I
 and TAU
P301L
 transgenes [18] with lack of 
NRF2 expression. The absence of NRF2 led to earlier onset of the disease, with more severe 
amyloidopathy and tauopathy and exacerbated cognitive defects. This study demonstrates for the 
first time the importance of homeostatic functions regulated by NRF2 in the brain pathophysiology 
of AD and represents a new tool for interventional studies.  
 
MATERIAL AND METHODS 
Transgenic mice 
 Colonies of NRF2-KO mice and NRF2-WT littermates were described previously [19]. 
Heterozygous APP
V717I
 mice (FVB/N), expressing the hAPP695 isoform with the V717I mutation 
under the control of the mouse Thy1 gene promoter, were crossed with C57/BL6j-NRF2-WT (APP-
NRF2-WT) or C57/BL6j-NRF2-KO (APP-NRF2-KO). Similarly, TAU
P301L
 mice (FVB/N), 
expressing homozygously the longest isoform of protein TAU with the P301L mutation (TAU 
4R/2N P301L) under control of the same mouse Thy1 gene promoter, were crossed with C57/BL6j-
NRF2-WT (TAU-NRF2-WT) or C57/BL6j-NRF2-KO (TAU-NRF2-KO). APP/TAU-NRF2-WT 
(AT-NRF2-WT) and APP/TAU-NRF2-KO (AT-NRF2-KO) in C57/BL6j background were obtained 
by crossing the above described genotypes for more than eight generations. Genotypic 
characterization of the APP
V717I
 and TAU
P301L
 transgenic mice was described previously [18; 20; 
21].  
RNA microarray expression analysis 
 Total mouse RNA was obtained from brain tissue by Trizol extraction (Invitrogen, 
California, USA) according to manufacturer’s instruction and as previously described [22]. RNA 
quality was determined using a bioanalyzer (Agilent, California, USA). RIN values of all samples 
were greater than 9.5. For expression analysis 50 ng of each total RNA sample was converted and 
amplified to cDNA using the Ovation® Pico WTA System V2 according to manufacturer’s 
instructions. Products were then hybridized on Mouse Gene 2.0 ST arrays containing probe sets for 
>28,000 coding and >7,000 non-coding transcripts. The functional clustering tool DAVID (Database 
for Annotation, Visualization and Integrated Discovery) v6.7 [23]  was used to look for functional 
enrichment of genes with more than 3-fold of change and adjusted p-value (FDR/BH) > 0.05 (644 
genes). The number of genes analyzed in AD brain cohorts was: i) 214 from [24], ii) 860 from [25], 
iii) 156 from [26], iv) 743 from [27] , v) 1785 from [28] and vi) 2027 from [29]. The number of 
genes analyzed in ageing brain cohorts were: i) 399 genes from [30], ii) 801 from [31], iii) 247 from 
[32]. Pathway analysis was performed with the Gene Ontology Biological Process 
(GOTERM_BP_FAT). 
Analysis of mRNA levels 
 Total RNA extraction, reverse transcription and quantitative PCR were done as detailed 
elsewhere [33]. Primer sequences are shown in Suppl. Table S1. To ensure that equal amounts of 
cDNA were added to the PCR, the housekeeping genes ActB, Gapdh and Tbp were amplified. Data 
analysis was based on the ΔΔCT method with normalization of the average data of housekeeping 
genes. All PCRs were performed in triplicate. 
Immunofluorescence, immunohistochemistry and immunoblotting 
 For immunofluorescence and immunohistochemistry, 30 µm-thick and 5 µm-thick sections 
from fixed brains and frozen spinal cords, respectively, were immunostained as described [33; 34]. 
Immunoblots were performed as described in [35]. Primary antibodies are annotated in Suppl. Table 
S2.  
TAU extraction and oligomeric Aβ detection 
   Hippocampus, brainstem and spinal cord were homogenized as described in [34]. Sarkosyl 
soluble and insoluble TAU was run on 7.5% SDS-PAGE gels and transferred to PVDF membranes 
in low methanol transfer buffer (6.6 % methanol, 25 mM Tris and 192 mM Glycine). Hippocampal 
samples were fractionated by a four step extraction method previously described [36]. One hundred 
micrograms of protein per sample was electrophoresed on 10-20% SDS-polyacrylamide Tris-tricine 
gels (Bio-Rad). Proteins were transferred to PVDF and membranes were boiled in PBS for 5 min 
after immunoblotting. 
Morris water maze test 
 After a 1-day habituation trial (day 0) in which preferences between quadrants in the 
different experimental groups were ruled out, the animals learned to find a hidden platform over the 
following 5 days, through 4 trials/day, 60 s each trial, plus 20 s in the platform. If an animal failed to 
reach the platform, it was placed on it by the experimenter. Subsequently, the animals were subjected 
to two trials on the 7th day, the first without the platform to assess possible differences in swimming 
speed and preference for the platform quadrant. And in the second, a cued version protocol using a 
visible platform was conducted to determine sensorimotor and motivational status of the animals. 
The animal behavior was recorded through an automated tracking system (Smart video tracking 
system, version 2.0.14, Panlab; Harvard Apparatus). 
Electrophysiological recordings 
 Data were obtained from six urethane-anaesthetized (1.6 g/ kg i.p.) adult mice per group as 
described in [37]. Briefly, field potentials were recorded through tungsten macroelectrodes (1 MΩ; 
World Precision Instruments) stereotaxically implanted in the dentate gyrus (A:-2,3; L: 2; H: 3.5 mm 
from bregma) according to the Paxinos and Watson Atlas. Twisted bipolar electrodes for electrical 
stimulation were aimed at the perforant path (A: -2.5; L: 0.5; H: 3.5 mm from bregma). Baseline 
recordings were taken with test stimuli (10-50 µA, 0.3 ms, 0.5 Hz) during 15 min before tetanic 
stimulation consisting of three pulse trains of 10-50 µA, lasting each pulse 0.3 ms and at 50 Hz. 
Trains lasted 500ms and the inter-train interval was 2 s. Recording was maintained for 30 min after 
tetanic stimulation. Field potentials were 0.1 Hz–1 kHz band-pass filtered, amplified (P15 Amplifier, 
Grass Co., USA), and digitized at 10 kHz (CED 1401; Cambridge Electronic Design). Signals 
analysis was carried out with Spike 2 software (Cambridge Electronic Design, Cambridge, UK). 
Field potential segments of 5 min were analyzed to obtain the response average. The mean average 
response during the 15 min period before the tetanic stimulation was considered as 100%. 
Recordings were accepted for analysis when baseline variability was less than 10%. 
Determination of reduced and oxidized glutathione, protein carbonyl and malondialdehyde 
content 
 Brain samples were homogenized in 1 ml phosphate buffer and submitted to the protocol 
described in [38]. 
Image analysis and statistics 
 Calculations of the false discovery rates (FDR) were done accordingly with Benjamini 
Hochberg’s FDR [39] employing IBM SPSS statistics 22 software. Adjusted p-value (FDR/BH) of 
≤0.05 was considered significant. Band intensities corresponding to immunoblot detection of protein 
samples were quantified using Image J 1.48 software. Calculation of p-values from ANOVA one-
way followed by Neiman-Kleuls post-hoc test, ANOVA two-way followed by Bonferroni post-hoc 
test and Student's t test were assess by GraphPad Prism 5 software among groups. A p value of ≤0.05 
was considered significant. Unless otherwise indicated, all experiments were performed at least three 
times with similar results. Values presented in the graphs are means of at least three samples. Results 
are expressed as mean ± SEM. 
 
RESULTS 
NRF2-deficient mouse brain replicates pathway alterations found in human elderly and AD 
brains 
 A microarray analysis of 25,293 genes was performed with brain samples from NRF2-
knockout (NRF2-KO) vs. wild type (NRF2-WT) mice. We found significant up-regulation of 510 
genes and down-regulation of 134 genes as assessed by more than 3-fold change expression and 
adjusted p≤0.05 (FDR/BH) (Suppl. Table S3). As shown in Table 1, we confirmed that the Nfe2l2 
gene, coding NRF2, was not expressed in NRF2-KO animals (effect change = -3.23 and adjusted p = 
0.035 (FDR/BH)). Among other altered genes, we validated the down-regulation of Gstm1, regulated 
by NRF2 [40] and Kras [41] and Wdfy1 [42] involved in cell signaling and inflammation. We also 
found up-regulation of Zbtb21/ZNF295, which has been implicated in Down syndrome and cognitive 
deficit [43]. These genes were further classified in functional clusters of biological processes by 
employing GOTERM_BP_FAT category (Suppl. Table S4) and compared with 3 cohorts of old 
human brain and 6 of AD brain (Fig. 1). All altered pathways in NRF2-KO brain mice were found to 
be also altered in either human ageing or AD brains, although some others were only altered in 
elderly subjects or AD patients but not in mice (Fig. 1C). Among the 20 gene clusters with the 
highest changes, aging and NRF2-KO groups share seven, AD and NRF2-KO groups share ten and 
the three groups combined share six (Fig. 1A and 1B). Altogether, these results show overlap in 
many dysregulated processes in the brain of NRF2-deficient mice, old people and AD patients and 
suggest the participation of NRF2 in the pathological process of AD.  
Characterization of APP
V717I 
and TAU
P301L
 expression in mice with presence or absence of 
NRF2 
 Based on the overlapping alterations indicated above, and to determine if NRF2 deficiency  
might participate in AD pathology, we generated transgenic mice with combined neuronal 
expression of human mutant hAPP
V717I
 and hTAU
P301L
 proteins (for simplicity from now on denoted 
AT) under the neuronal Thy1 promoter in the C57/bl6 genetic background, with either wild type 
(AT-NRF2-WT) or NRF2 absence (AT-NRF2-KO). The combined expression of these transgenes 
has been described previously in wild type mice [18]. Both AT-NRF2-WT and AT-NRF2-KO mice 
exhibited short lifespan as expected from severe tauopathy [18; 21; 44]. Thus, the mean lifespan of 
AT-NRF2-WT and AT-NRF2-KO mice was 15 and 12 months, respectively (to be described 
elsewhere). Although the pathway analysis by biological process demonstrated significant alterations 
of ROS management and metabolism, as expected from previous reports [15; 34], many targets of 
NRF2 did not exhibit significant changes in the microarray analysis (see Discussion). Therefore, to 
more closely determine the effects of NRF2-deficency on brain homeostasis, we explored markers of 
oxidative and inflammatory stress as these factors are tightly linked to NRF2 homeostatic 
adaptations [7; 33; 45; 46]. As shown in Fig. 2A-C, AT-NRF2-KO brains exhibited lower levels of 
reduced glutathione and higher levels of carbonylated proteins (adducts of 
2,4.drinitrophenylhydrazzine, DNPH) and lipid peroxides (malondialdheyde, MDA) than AT-NRF2-
WT mice. Regarding neuroinflammation, the levels of some pro-inflammatory markers, IL6, COX2 
and iNOS, were modestly but significantly increased in AT-NRF2-KO vs. age-matched AT-NRF2-
WT mice (Fig. 2D-G). These results are consistent with a preventive effect of NRF2 against low-
grade chronic oxidative and inflammatory stress in the brain, which are two hallmarks of ageing and 
AD onset and progression. 
Phosphorylated  TAU and Aβ*56 oligomers are increased in hippocampus of AT-NRF2-KO 
mice 
 We next compared the phosphorylation status of TAU in hippocampus, brainstem and spinal 
cord by immunohistochemistry with the AT8 antibody, specific for phosphorylated hTAU at residues 
Ser
202
 and Thr
205
 (p-TAU) (Fig. 3E). As shown in Fig. 3A, no major differences in p-TAU-AT8 were 
observed in hippocampi of AT-NRF2-WT and AT-NRF2-KO mice. Neurons of the pontine reticular 
formation (Fig. 3B) contain p-TAU-AT8 in both genotypes, exhibiting intracellular p-TAU 
aggregates and thick dystrophic neurites. While most p-TAU-positive neurites were traceable in AT-
NRF2-WT mice, these fibers were disorganized in AT-NRF2-KO mice (Fig. 3C). In the spinal cord 
(Fig. 3D), the motor neurons of the anterior horn also exhibited disorganized patterns, with a 
characteristic ballooned morphology of dystrophic fibers [47]. As shown in Fig. 3E and 3G, three 
forms of p-TAU
P301L
 in the sarkosyl-insoluble fraction (SI) were separated by SDS-PAGE and 
termed hP1, hP2 and hP3, according to their lesser mobility caused by augmented phosphorylation 
[48; 49]. Densitometric quantification revealed that the less phosphorylated faster migrating hP1 
form was most abundant in the sarkosyl-soluble fraction (SS) while the most phosphorylated slower 
migrating hP3 form was mainly found in the SI fraction. AT-NRF2-KO mice exhibited higher levels 
of hP2 and hP3 in the SI fraction than AT-NRF2-WT mice. These biochemical results confirmed the 
tauopathy observed immunohistochemically in the brainstem and spinal cord. 
Hippocampal sections stained for APP/Aβ (4G8 antibody) revealed more and larger 
intracellular vesicles in neurons of AT-NRF2-KO compared with AT-NRF2-WT mice, particularly 
in the subiculum (Fig. 4A-B) as expected [34]. We analyzed the levels of Aβ-oligomeric species that 
have been proposed to correlate with cognitive impairment in humans. Hippocampi from AT-NRF2-
WT and AT-NRF2-KO mice were separated in soluble (SF) (Fig. 4A, 4C) and membrane bound 
(MF) (Fig. 4A, 4D) fractions as described [36]. We did not detect significant differences in the levels 
of APP, sAPPα, sAPPβ, CTF/Aβ (3-mer), Aβ (6-mer) or Aβ (2-mer). Interestingly, NRF2 deficiency 
increased the levels of the presumed toxic Aβ*56 oligomer in both SF and MF fractions (Fig. 4E). 
The levels of mRNA encoding enzymes involved in APP processing, i.e. ADAM10, ADAM17, 
BACE1 and PS1, were not significantly altered by the lack of NRF2 (data not shown). Therefore, 
increased A*56 levels should be related to either oxidative alterations of the amyloidogenic 
pathway or impaired clearance of the oligomers. In any case, NRF2-deficiency increased the levels 
of the potentially toxic proteins p-TAU and Aβ*56 and suggest a cell autonomous mechanism of 
neuronal damage in the absence of NRF2 defense. 
NRF2 deficiency aggravates learning and memory deficits induced by amiloydopathy and 
tauopathy 
 We analyzed the spatial acquisition and retention memory in 6-months-old NRF2-WT, 
NRF2-KO, AT-NRF2-WT and AT-NRF2-KO mice using the Morris water maze test. Swim speed 
was similar at this age for all genotypes, indicating uncompromised motor competency (data not 
shown). After five days of training, mice landed on the platform in less than 30 s except AT-NRF2-
KO mice, who took significantly longer (Fig. 5A). On the fifth day, the platform was removed and 
the mice were also tested for their memory of the platform location (Fig. 5B). All mice, again with 
exception of the AT-NRF2-KO, exhibited a tendency to swim in the target sector where the platform 
used to be located. AT-NRF2-KO mice, however, displayed circling and tumbling swimming-tracks, 
indicating their incapacity to remember the original location of the platform. These results 
demonstrated impaired cognition already at 6 months of age in the AT-NRF2-KO mice despite 
lacking obvious amyloid load or TAU pathology (data not shown and [18]).  
Further exploration of cognitive function was performed electrophysiologically for 
hippocampal long term potentiation (LTP) in 6-months-old mice. The synaptic transmission in the 
neurons of the dentate gyrus was recorded in response to performant path stimulation (Fig. 5C). High 
frequency stimulation increased the field excitatory post-synaptic potential (fEPSP) in control NRF2-
WT mice and to a lesser extent in AT-NRF2-WT and AT-NRF2-KO mice. This was expected, given 
the combined proteinopathy, but surprisingly there was lower LTP in the parental NRF2-KO mice, 
for the first time indicating that NRF2-deficiency in itself reduced the LTP in these hippocampal 
regions. We concluded that combined expression of human mutant APP and TAU with NRF2 
depletion substantially compromised the electrophysiological capacity of neurons in the 
hippocampus.  
DISCUSSION 
The use of network techniques to study alteration of brain functional pathways in the context 
of human ageing and AD allowed us to recreate some of the links shared in common with NRF2-
deficiency, a master regulator of cellular homeostasis. In line with previous reports [15; 34], the 
microarray data did not show significant changes in expression of well-known NRF2 targets. This is 
most likely related to the low basal expression of NRF2 in brain. However, this study illustrates that 
subtle changes in NRF2-regulated genes may have a strong amplification in other pathophysiological 
pathways and uncovers crucial mechanisms that might have passed unnoticed in AD. In this regard, 
it is interesting to note that NRF2-encoding NFE2L2 haplotypes influence AD progression [13]. 
Based on the transcriptomics data, in a reverse translational approach, from man to mice, we 
introduced NRF2-deficiency as a novel variable. Previous studies have addressed the relevance of 
NRF2 in AD by combining NRF2 deficiency with either amyloidopathy [14; 17] or tauopathy [17] 
alone, but not in combination as presented here. These studies suggested that depletion of NRF2 
activity might aggravate AD-related phenotypes but were unable to address the interactions between 
NRF2 expression and both pathologies when present, as they are in human disease, together. We 
emphasize this point because in humans, AD is by definition a combination of both hallmarks and it 
is still not clear what their mutual relation is, or what the contribution of each is in the development 
of idiopathic, sporadic AD. 
In fact, we observed that the hippocampus of AT-NRF2-KO mice exhibited increased levels 
of oxidative and pro-inflammatory markers compared to AT-NRF2-WT mice, suggesting that the 
proteotoxic challenge, brought about by human APP and TAU, rendered them more sensitive to 
oxidative and inflammatory stress. Low-grade persistent oxidative stress is a characteristic of mild 
cognitive impairment indicating that low grade oxidative stress and probably inflammatory stress are 
early events in AD [50; 51; 52].  
Memory and learning were severely impaired in the AT-NRF2-KO mice as early as 6 
months, and preceding the presence of amyloid plaques and TAU fibrillar aggregates. These findings 
suggest that lack of NRF2 replicates a prodromal condition of human AD that is aggravated by loss 
of NRF2-related homeostasis and is in line with other findings from animal models of disease related 
phenotypes before neurodegeneration [53; 54]. 
An additional argument for the contribution of NRF2 to AD is its decline in activity with 
ageing, which remains the main risk factor for sporadic AD [55; 56]. The well-established genes 
with high impact in familial AD have a small incidence at the population level (APP, PS1, PS2). We 
envision NRF2 as a gene with a relatively small contribution to AD penetrance but with a large 
impact on the general population, particularly in the elderly where NRF2 activity is low because of 
genetic and as yet unknown environmental reasons. A consequence of this study is the generation of 
a mouse model that combines impaired homeostatic responses with proteinopathy and paves the way 
to future new pharmacological strategies aimed at NRF2 as the molecular target for treatment of the 
cognitive impairment in MCI and early AD. 
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Figure 1. Comparison of the functional pathways altered in brain of NRF2-KO mice vs. human 
ageing and AD cohorts. Altered gene expression in NRF2-KO mice was analyzed in brain samples 
from 11-months-old NRF2-WT (n = 4 males) vs. NRF2-KO mice (n = 4 males). Comparison with 
human ageing and AD brain cohorts was done as indicated in Material and Methods. A, Venn 
diagram showing the overlapping distribution of functional pathways in AD, ageing and NRF2-null 
brains. Cluster numbers correspond to: 1, regulation of cell signaling; 2, phosphorous and phosphate 
metabolism; 3, cellular protein metabolic process; 4, neurodevelopment; 5, regulation of cell death; 
6, protein complex assembly; 7, intracellular transport and protein location; 8, nucleoside, purine and 
ATP metabolism;  9, regulation of cell cycle; 10, acetylcholine metabolism; 11, transmembrane 
transport of ions; 12, synaptic function; 13, cognition, learning and memory; 14, host response to 
infection; 15, lipid and alcohol metabolism; 16, interspecies and multi-organ modulation; 17, 
secretory and exocytic pathways; 18, regulation of membrane and vesicles; 19, regulation of 
cytoskeleton; 20, regulation of angiogenesis; 21; protein modification by conjugation; 22, regulation 
of cell-environment interaction; 23, glucose metabolism; 24, cell morphogenesis; 25, immune 
response; 26, ROS metabolic process; 27, cellular motility; 28, regulation of transmembrane 
transport; 29, development of peripheral tissues. B and C, summary of selected categories as 
calculated by DAVID. The categories are ranked according to -log10 P-values. 
Figure 2. Low-grade oxidative and inflammatory stress in AT-NRF2-KO mice. A, levels of reduced 
glutathione (GSH) normalized with total oxidized glutathione (GSSG). B, protein carbonyl content 
as determined by DNPH levels. C, thiobarbituric acid-reactive substances (TBARs) representing 
mostly MDA. Data are mean ± SEM (NRF2-WT= 4 males; NRF2-KO=4  males; AT-NRF2-WT = 2 
males and 2 females; AT-NRF2-KO= 2 males and 2 females). Statistical analysis was performed 
with a one-way ANOVA followed by Neiman Keuls post-hoc test. *p≤0.05, ***p≤0.001 vs. NRF2-
WT group. D, immunoblot analysis of IL6, COX2 and NOS2 in brain homogenates from mice of the 
indicated genotypes. Protein levels of GAPDH were analyzed to ensure similar load per lane. E, F 
and G, densitometric quantification of representative blots from B. Data are mean ± SEM (NRF2-
WT= 2 males and 1 female; NRF2-KO= 3 males; AT-NRF2-WT = 2 males and 1 female; AT-NRF2-
KO= 2 males and 1 female). Statistical analysis was performed with a one-way ANOVA followed by 
Neiman Keuls post-hoc test. *p≤0.05, **p≤0.01 vs. NRF2-WT group. 
Figure 3. Lack of NRF2 leads to increased levels of insoluble TAU
P301L
 in brain and spinal cord. 
Immunostaining with antibody against p-TAU (AT8) in hippocampal CA1 and subiculum zones (A), 
pontine reticular formation (B and C) and spinal cord (D) from 11-month old AT-NRF2-WT and 
AT-NRF2-KO mice. The spinal cord sections were counterstained with hematoxylin. For A, B and 
C, the plates show representative preparations from NRF2-WT (2 males and 1 female) and NRF2-
KO (2 males and 1 female) mice. E, scheme of protein TAU-4R showing the phosphorylated 
residues recognized by the indicated antibodies. F, immunoblot analysis of sarkosyl-insoluble (SI) 
and sarkosyl-soluble (SS) pTAU levels in hippocampus, brainstem and spinal cord homogenates 
respectively from AT-NRF2-WT and AT-NRF2-KO mice employing anti-PHF1 antibody. G, 
densitometric quantification of representative blots from F. Data are mean ± SEM (AT-NRF2-WT = 
5 males and 1 female; AT-NRF2-KO = 3 males and 3 females). Statistical analysis was performed 
with Student’s t test. *p≤0.05, comparing AT-NRF2-WT and AT-NRF2-KO groups. 
Figure 4. NRF2 deficiency leads to Aβ*56 accumulation. A, scheme showing APP processing by α-, 
β- and γ-secretase and the location of the epitopes recognized by the antibodies employed in western 
blot analysis. (SF, soluble fraction and MF, membrane fraction). B, immunohistochemical analysis 
of APP/Aβ expression in hippocampus of 11-month old AT-NRF2-WT and AT-NRF2-KO mice 
stained with anti 4G8 antibodies in CA1 and subiculum. C and D, immunoblots with the anti-Aβ 
antibody as indicated SF and MF fractions from hippocampal homogenates of AT-NRF2-WT and 
AT-NRF2-KO mice. The right two lanes show samples from APP/PS1 and wild type mice as 
positive and negative controls, respectively. The asterisk in D indicates a non-specific band present 
in all samples including the negative control. β-actin detection demonstrates similar loading across 
lanes. E, densitometric quantification of blots depicted in C and D. Data are mean ± SEM (AT-
NRF2-WT = 5 males; AT-NRF2-KO = 4 males and 1 female). Statistical analysis was performed 
with a Student’s t test. *p≤0.05, comparing AT-NRF2-WT and AT- NRF2-KO groups 
Figure 5.  NRF2 deficiency impairs long term potentiation, and spatial learning and memory. A, 
acquisition time to reach the hidden platform in five trials during Morris water maze test of 6-months 
old-mice of the indicated genotypes.  Data are mean ± SEM (NRF2-WT = 5 males and 5 females; 
NRF2-KO = 5 males and 5 females; AT-NRF2-WT = 6 males and 4 females; AT-NRF2-KO = 5 
males and 5 females). Statistical analysis was performed with two-way ANOVA followed by 
Bonferroni post-hoc test. *p≤0.05 and **p≤0.01 versus NRF2-WT group. B. Upper circles, 
representative swimming tracks of the indicated genotypes during the probe phase in which the 
platform had been removed. Lower panel, quantification of the frequency to cross to the platform 
quadrant. Statistical analysis was performed with a one-way ANOVA followed by Neiman Keuls 
post-hoc test. *p<0.05 vs. NRF2-WT group. C, Upper registries correspond to representative 
responses recorded before (thin line) and after (thick line) high-frequency trains of tetanic 
stimulation. Calibration: 2 mV, 20 ms. The graph shows LTP of 6-months-old animals from the 
indicated genotypes. Data are mean ± SEM (n = 6). Statistical analysis was performed with two-way 
ANOVA followed by Bonferroni post-hoc test. **p < 0.01, and ***p < 0.001 comparing AT-NRF2-
KO versus NRF2-WT group. 
###
p< 0.001 comparing NRF2-KO vs NRF2-WT group. 
$$$ 
p< 0.001 
comparing AT-NRF2-WT versus NRF2-WT group. 
 
 



  
  
TABLE 1 Microarray validation by qRT-PCR. The expression data obtained using microarrays for selected 
genes was validated using qRT-PCR analysis. Fold of change in mRNA of the indicated genes was calculated 
relative to NRF2-WT brains and normalized to the average expression of ActB, Tbp and Gapdh house keeping 
genes. Data are mean ± SEM (n=4). 
  Microarray qRT-PCR  
Gene Entrez ID Gene 
name 
Effect 
change 
p-value 
(FDR/BH) 
NRF2-WT NRF2-KO p-value 
(t-student) 
14862 Gstm1 -3,87 0.0082 1.00±0.11 0.23±0.08 0.001 
16653 Kras -5.10 0.0022 1.00±0.13 0.64±0.07 0.042 
69368 Wdfy1 -6.97 0.00043 1.00±0.12 0.60±0.09 0.023 
114565 Zbtb21 11.36 0.000078 1.00±0.44 4.00±0.40 0.002 
 
 
 
 
 
 
 
 
 
  
 Highlights 
 NRF2-lack mimics many transcriptomic alterations of elderly and AD patients. 
 APP/TAU-induced oxidative and inflammatory stress is exacerbated by NRF2-deficiency. 
 APP/TAU-induced proteinopathy is exacerbated by NRF2-deficiency. 
 APP/TAU-induced deficits in cognition are aggravated by NRF2-deficiency. 
